RT Journal Article
SR Electronic
T1 Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.27.22276959
DO 10.1101/2022.06.27.22276959
A1 Suntronwong, Nungruthai
A1 Assawakosri, Suvichada
A1 Kanokudom, Sitthichai
A1 Yorsaeng, Ritthideach
A1 Auphimai, Chompoonut
A1 Thongmee, Thanunrat
A1 Vichaiwattana, Preeyaporn
A1 Duangchinda, Thaneeya
A1 Chantima, Warangkana
A1 Pakchotanon, Pattarakul
A1 Chansaenroj, Jira
A1 Nilyanimit, Pornjarim
A1 Srimuan, Donchida
A1 Thatsanatorn, Thaksaporn
A1 Sudhinaraset, Natthinee
A1 Wanlapakorn, Nasamon
A1 Mongkolsapaya, Juthathip
A1 Poovorawan, Yong
YR 2022
UL http://medrxiv.org/content/early/2022/06/27/2022.06.27.22276959.abstract
AB This study examined the neutralizing activity and receptor binding domain (RBD) antibody levels against wild-type and omicron BA.1 and BA.2 variants in individuals who received three doses of COVID-19 vaccination. The relationship between the SARS-CoV-2 RBD antibody against wild-type and live virus neutralizing antibody titers against omicron BA.1 and BA.2 variants was examined. In total, 310 sera samples from individuals after booster vaccination (third dose) vaccination were tested for specific IgG wild-type SARS-CoV-2 RBD and the omicron BA.1 surrogate virus neutralization test (sVNT). The live virus neutralization assay against omicron BA.1 and BA.2 was performed using the foci-reduction neutralization test (FRNT50). The anti-RBD IgG strongly correlated with FRNT50 titers against BA.1 and BA.2. Non-linear regression showed that anti-RBD IgG with ≥148 BAU/mL and ≥138 BAU/mL were related to detectable FRNT50 titers (≥1:20) against BA.1 and BA.2, respectively. A moderate correlation was observed between the sVNT and FRNT50 titers. At detectable FRNT50 titers (≥1:20), the predicted sVNT for BA.1 and BA.2 were ≥10.57% and ≥11.52%, respectively. The study identified anti-RBD IgG and sVNT levels that predict detectable neutralizing antibodies against omicron variants. Assessment and monitoring of protective immunity support vaccine policies and will help identify optimal timing for booster vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the National Research Council of Thailand (NRCT), the Health Systems Research Institute (HSRI), the Center of Excellence in Clinical Virology of Chulalongkorn University, King Chulalongkorn Memorial Hospital, MK Restaurant Group, and the Second Century Fund Fellowship of Chulalongkorn University. Thaneeya Duangchinda was funded by the National Center for Genetic Engineering and Biotechnology, BIOTEC Platform No. P2051613.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was performed following the Declaration of Helsinki and Good Clinical Practice principles. The study protocol was reviewed and approved by the Institutional Review Board of the Faculty of Medicine of Chulalongkorn University (IRB numbers 871/64 and 690/64).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are provided in the manuscript and supplementary files. Additional information can be requested from the corresponding author